Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Jaguar Health Inc
JAGX
Healthcare
Biotechnology
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing...
prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:JAGX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 02, 2024 8:30pm
Jaguar Health Participating in December 3-5 Pet Connect Conf
Just In: $JAGX Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 22, 2024 2:45pm
Jaguar Health Seeking Partner to Develop and Commercialize N
NEWS: $JAGX Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in DogsDiarrhea is one of the
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 20, 2024 9:15pm
Key Collaborator of Jaguar Health Joint Venture Magdalena Bi
Breaking News: $JAGX Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association AwardMagdalena Biosciences, a joint venture formed by Jaguar
...more
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 02, 2024 4:53pm
Jaguar Health, Inc. (NASDAQ:JAGX) – Diversifying into
https://beyondspx.com/2024/07/31/jaguar-health-inc-nasdaqjagx-diversifying-into-cancer-supportive-care-with-promising-rare-disease-pipeline/
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 08, 2024 1:16pm
Issuance of New European & Australian Patents Bolster IP Pro
JUST IN: $JAGX Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)New
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 21, 2024 5:00pm
Jaguar Health Reports Approval of All Proposals at June 2024
BREAKING NEWS: $JAGX Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of StockholdersJaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 14, 2024 8:10am
New Press Release - Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 millionTop line results expected to be imminent...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 13, 2024 12:38pm
New Press Release - REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an...
read article.
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 09, 2024 2:00pm
Jaguar Health Announces Submission of Clinical Trial Applica
Breaking News: $JAGX Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 16, 2024 1:30pm
Why Jaguar Health Stock Is Up Today | Benzinga
News; $JAGX Why Jaguar Health Stock Is Up Today | BenzingaJaguar Health, Inc. (NASDAQ:JAGX) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 16, 2024 11:00am
Jaguar Health Signs exclusive 5-year In-license Agreement
Just In: $JAGX Jaguar Health Signs exclusive 5-year In-license Agreement2024-04-16 10:15:17 ET DENVER, Colo., Apr 16, 2024 ( 247marketnews.com )- Jaguar Health, Inc. (NASDAQ: JAGX ) reported signing
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 16, 2024 10:45am
Jaguar Health Licenses FDA-Approved Oral Mucositis Product f
JUST IN: $JAGX Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive CareJaguar planning to begin
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 16, 2024 10:30am
Don't Trade Penny Stocks Until You've Taken These Steps
Breaking News: $JAGX Don't Trade Penny Stocks Until You've Taken These Steps2024-04-16 06:51:00 ET 3 Steps to Take Before You Start Trading Penny Stocks in 2024 Penny stocks offer an exciting
...more
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Mar 04, 2024 4:53pm
RE:JAGX. only 340million shares trade during reg hrs
I'll go out on a limb and say...... here comes a Reverse split announcement Mark this ; )
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 04, 2024 4:52pm
JAGX. only 340million shares trade during reg hrs
Add 23 million more in AH Last NR was in Feb.... Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance 2024-02-23 05:33 ET - News Release SAN
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight